Back to Authors

Khelimskii, Dmitrii A.

0000-0001-5419-913X

Mayo Clinic

Meshalkin National Medical Research Center

Citations 1

Abstract 11505: Predicting In-Hospital All-Cause Mortality in Chronic Total Occlusion Percutaneous Coronary Intervention: PROGRESS-CTO Mortality Score
Karácsonyi, Judit , Göktekín, Ömer , Guindy, Ahmed El, Chandwaney, Raj, Patel, Mitul , Karmpaliotis, Dimitrios, Rangan, Bavana V. , Sandoval, Yader , Choi, James W. , Nicholson, William , Jaber, Wissam , Rinfret, Stéphane , KUTUZIS, MICHAEL, Yeh, Robert W. , Mastrodemos, Olga , Simsek, Bahadir , Kostantinis, Spyridon , Alaswad, Khaldoon , Krestyaninov, Oleg V. , Khelimskii, Dmitrii A. , Davies, Rhian E. , Görgülü, Şevket , Khatri, Jaikirshan J , Jaffer, Farouc A , KUTUZIS, MICHAEL, Tsiafoutis, Ioannis N. , Burke, M. Nicholas , Allana, Salman , Brilakis, Emmanouil S.

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.11505 Get It

Introduction: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with increased risk of periprocedural complications. Estimating the risk of complications facilitates risk-benefit assessment and procedural planning. Methods: We analyzed the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO, NCT02061436) and created a risk score for in-hospital all-cause mortality. Logistic regression prediction modeling was used to identify independently associated variables and the model was internally validated with bootstrapping. Results: Of the 10,480 CTO PCI cases performed between 2012-2022 at 40 US and non-US centers, in-hospital mortality occurred in 47 (0.45%). The final prediction model identified 4 independent predictors of mortality: Age ≥65 years, Odds Ratio [OR]: 2.83 (95% confidence interval [CI], 1.30-6.16), 1-point; Left ventricular ejection fraction ≤45%, OR: 2.13 (95% CI, 1.14-3.98), 1-point; Moderate-severe calcification, OR: 2.45 (95% CI, 1.18-5.08), 1-point; and Antegrade dissection re-entry, OR: 2.81 (95% CI, 1.06-7.43), 1-point; or Retrograde strategy, OR: 3.51 (95% CI, 1.67-7.37), 1-point; with a bootstrap corrected c-statistics of 0.71 (95% confidence interval: 0.63-0.81). The calculated risk percentages for mortality based on the PROGRESS-CTO mortality score ranged from 0.05-2.42% for mortality, and 63% of patients in the PROGRESS-CTO cohort had PROGRESS-CTO mortality score of 1 or 2, corresponding to a mortality risk of 0.1-0.5% (Figure 1). Conclusions: The PROGRESS-CTO in-hospital mortality risk score can facilitate risk-benefit assessment and procedural planning in patients undergoing CTO PCI.